Financial Times -- GlaxoSmithKline might shift outside the UK a planned £300m investment to develop and manufacture its next generation of medicines unless the government rapidly implements new tax incentives. In a statement, the UK-based pharmaceuticals group praised plans for new tax relief on income from patents developed by innovative companies in this week’s pre-Budget report, but warned it would need to apply to drugs already under development.
